Esophageal Diseases  >>  MK-2206  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-2206 / Merck (MSD)
S1005, NCT01260701: Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
75
US, Canada
Akt Inhibitor MK2206, MK2206
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
05/14
07/15

Download Options